Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors

  • J Med Chem. 2012 Oct 25;55(20):8859-78. doi: 10.1021/jm3011542.
Tao Liu  1 ,  Somarajan J Nair ,  André Lescarbeau ,  Jitendra Belani ,  Stéphane Peluso ,  James Conley ,  Bonnie Tillotson ,  Patrick O'Hearn ,  Sherri Smith ,  Kelly Slocum ,  Kip West ,  Joseph Helble ,  Mark Douglas ,  Adilah Bahadoor ,  Janid Ali ,  Karen McGovern ,  Christian Fritz ,  Vito J Palombella ,  Andrew Wylie ,  Alfredo C Castro ,  Martin R Tremblay
Affiliations
  • 1. Infinity Pharmaceuticals, Inc., 780 Memorial Drive, Cambridge, Massachusetts 02139, USA.
Abstract

Misregulation of protein translation plays a critical role in human Cancer pathogenesis at many levels. Silvestrol, a cyclopenta[b]benzofuran natural product, blocks translation at the initiation step by interfering with assembly of the eIF4F translation complex. Silvestrol has a complex chemical structure whose functional group requirements have not been systematically investigated. Moreover, silvestrol has limited development potential due to poor druglike properties. Herein, we sought to develop a practical synthesis of key intermediates of silvestrol and explore structure-activity relationships around the C6 position. The ability of silvestrol and analogues to selectively inhibit the translation of proteins with high requirement on the translation-initiation machinery (i.e., complex 5'-untranslated region UTR) relative to simple 5'UTR was determined by a cellular reporter assay. Simplified analogues of silvestrol such as compounds 74 and 76 were shown to have similar cytotoxic potency and better ADME characteristics relative to those of silvestrol.

Products